within Pharmacolibrary.Drugs.ATC.L;

model L01EX14
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.3266666666666667,
    adminDuration  = 600,
    adminMass      = 0.6,
    adminCount     = 1,
    Vd             = 0.551,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013666666666666666,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Entrectinib is an orally administered, selective tyrosine kinase inhibitor targeting TRKA, TRKB, TRKC, ROS1, and ALK. It is primarily indicated for the treatment of solid tumors with NTRK gene fusions and ROS1-positive non-small cell lung cancer (NSCLC). Entrectinib is approved for clinical use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported for adult patients with solid tumors following oral administration.</p><h4>References</h4><ol><li>Georgina Meneses-Lorente, Darren Bentley, Elena Guerini, Karey Kowalski, Edna Chow-Maneval, Li Yu, Andreas Brink, Nassim Djebli, Francois Mercier, Vincent Buchheit, Alex Phipps,Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.,Investigational new drugs,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33462752/'>https://pubmed.ncbi.nlm.nih.gov/33462752/</a></li><li>Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore-Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann D Johnson, Rupal Patel, David Luo, Edna Chow-Maneval, Zachary Hornby, Pratik S Multani, Alice T Shaw, Filippo G De Braud,Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).,Cancer discovery,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28183697/'>https://pubmed.ncbi.nlm.nih.gov/28183697/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX14;
